Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to unravel severe blood disorders in youth

NCT ID NCT03576742

Knowledge-focused Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed registry study followed 80 children and young adults with severe immune cytopenias, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome. Researchers observed participants over up to 4 years to improve diagnosis and track the disease course under various treatments. No new treatments were tested; the goal was to gather data to guide future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help doctors better diagnose and manage severe immune cytopenias in children and young adults.
What could go wrong
This is an observational study, not a treatment trial. It collects data only and does not test any new therapy, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Mar 2018

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

consecutive registration of pediatric, adolescent, and young adult patients with severe immune cytopenia who consent

Ages

6 months to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Autoimmune hemolytic anemia (AIHA) * Evans syndrome (ES) * Persistent or chronic immune thrombocytopenia (ITP; \>6 months after first manifestation) Exclusion Criteria: * (history of) malignancies * (history of) hematopoietic stem cell transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune hemolytic anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aplastic anemia autoimmune hemolytic anemia Evans syndrome inborn error of immunity Myelodysplastic Syndromes pancytopenia Primary Immunodeficiency Diseases Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune hemolytic anemia Evans syndrome Immune thrombocytopenia Primary immunodeficiency

Contacts and locations

Locations

  • Pediatric Hematology-Oncology Outpatient Clinic

    Graz, Styria, 8036, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.